Table 1 Baseline characteristics of patients with mCRPC starting treatment with abiraterone or enzalutamide.
Total | |
|---|---|
Patients [n] | 65 |
Age, median [years] (IQR) | 66 (62–76) |
Therapy [n] (%) | |
Abiraterone | 46 (70.8) |
Enzalutamide | 19 (29.2) |
Prior abiraterone or enzalutamide [n] (%) | 22 (33.9) |
Prior use of docetaxel [n] (%) | 25 (38.5) |
Line of therapy [n] (%) | |
1st | 33 (50.8) |
2nd | 15 (23.1) |
3rd or higher | 17 (26.2) |
PSA doubling time < 3 months [n] (%) | 28 (43.1) |
ECOG performance status (all) [n] (%) | |
0 | 53 (94.6) |
≥ 1 | 3 (5.4) |
Gleason-Score ≥ 8 [n] (%) | 47 (77.1) |
Median PSA at baseline [ng/ml] (IQR) | 24.3 (9.3–114.0) |
Median LDH at baseline [U/l] (IQR) | 223 (197–275) |
Median ALP at baseline [U/l] (IQR) | 106 (76–169) |
Hb < 12 g/dl [n] (%) | 21 (32.3) |
Elevated LDH at baseline [n] (%) | 27 (41.5) |
Elevated ALP at baseline [n] (%) | 21 (32.3) |
Bone protection [n] (%) | 14 (21.5) |
Presence of lymph node metastases [n] (%) | 37 (56.9) |
Presence of bone metastases [n] (%) | 51 (78.5) |
Presence of visceral metastases [n] (%) | 6 (9.2) |
